BioMedNewsBreaks – RYAH Group Inc. Enters Strategic Partnership to Establish Market Standard for Vaporizing

RYAH Group, a leading digital health care analytics and technology company, recently entered into a research-and-distribution arrangement with THC Lab. Appearing to be an ideal partner for RYAH as the company expands globally, THC Lab specializes in providing products and services to compounding pharmacies in Italy and other European countries in the specific field of medical cannabis. The agreement outlines the parameters for the launch of RYAH’s IoT dose-measuring Smart-Inhaler and data analytics platform in Italy as well as the Netherlands. “We are confident that together with RYAH we will be able to increase considerably the share of inhaled medical cannabis currently estimated at only 10% in Italy and around 20% in the Netherlands,” said THC Lab sales manager Andrea Ferrari in a recent update. “Our aim is to reach out to hundreds of pharmacies and establish RYAH as the market standard for vaporizing. We are extremely excited about this new partnership and see tremendous synergies with our other commercial as well as scientific activities in the medical cannabis sector.”

To view the full article, visit  https://ibn.fm/O2ApA

RYAH Group Inc.

RYAH Group is a leader in digital health care analytics and technology. By creating a suite of dose-measuring, IoT devices that capture data from seed to consumption, RYAH is positioned to unearth breakthrough discoveries capable of reshaping the understanding of plant-based medicine. For more information, visit the company’s website at https://www.RYAHGroup.com.

NOTE TO INVESTORS: The latest news and updates relating to RYAH Group are available in the company’s newsroom at https://ibn.fm/RYAH          

About BioMedWire

BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.biomedwire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.biomedwire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork